Hoth Therapeutics, Inc. (HOTH) announced on Tuesday encouraging preclinical results for its investigational Alzheimer's treatment, HT-ALZ. Following the announcement, the company's shares surged by over 15 percent in pre-market trading.
In a recent study, Alzheimer's model mice treated with HT-ALZ demonstrated a lower presence of reactive astrocytes compared to the vehicle-treated group. Astrocytes, the star-shaped cells in the nervous system, typically become reactive in response to various pathological conditions affecting the central nervous system. These cells are implicated in the progression of neurodegenerative diseases such as Alzheimer's. The study, which administered varying doses of HT-ALZ to the model mice, showed significant reductions in astrocyte activity in critical brain regions. This suggests a potential correlation between decreased astrocyte reactivity and enhanced cognitive function, according to the company's statement.
Robb Knie, CEO of Hoth Therapeutics, expressed optimism, stating, "The observed reductions in astrocyte activity and corresponding cognitive improvements with HT-ALZ bolster our confidence as we advance in our development process."
On Monday, Hoth Therapeutics stock closed at $1.01, reflecting an 8.18 percent decline. Over the past year, the stock has fluctuated between $0.5800 and $1.7900.
